title: Future alternatives for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae: what is in the pipeline?
abstract: The emergence and spread of carbapenemase-producing Enterobacteriaceae is an important and very concerning problem. There is an urgent need of new antibimicrobials for treating these infections. Currently there are some options in the pipeline. Several new beta-lactamase and carbapenemase inhibitors as avibactam and MK-7655, combined with old or new betalactams are a very interesting option. Some combinations as ceftazidime-avibactam are in the late stages of clinical development and could reach the market in the next years. New aminoglycosides as plazomicin, tetracycline derivates as eravacycline, and several other new molecules as monosulfactams are currently in different stages of development.
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital del Mar, Institut Hospital del Mar d'Investigació Mèdica (IMIM), Barcelona, Spain.
authors.forename: Juan Pablo
authors.initials: JP
authors.lastname: Horcajada
authors.affiliation: Unidad de Gestión Clínica de Enfermedades Infecciosas, Hospital Universitario Reina Sofía-IMIBIC-UCO, Córdoba, Spain.
authors.forename: Julián
authors.initials: J
authors.lastname: Torre-Cisneros
authors.affiliation: Servicio de Enfermedades Infecciosas, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: Peña
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain.
authors.forename: María Carmen
authors.initials: MC
authors.lastname: Fariñas
mesh_terms: D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015780:Carbapenems / Q000378:metabolism / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D005544:Forecasting; D006801:Humans; D018440:beta-Lactam Resistance / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D015780:Carbapenems; D015507:Drugs, Investigational; D001618:beta-Lactamases; C063912:carbapenemase
keywords: Avibactam; BAL-30072; Beta-lactamase inhibitors; Biapenem/RPX7009; Eravacilina; Eravacycline; Inhibidores de betalactamasas; Plazomicin; Plazomicina